EpiSwitch PSE
94% accurate prostate cancer blood test guiding who can proceed to biopsy or placed on surveillance.
The EpiSwitch® Prostate Screening Test (PSE) is a new prostate cancer blood test that boosts the accuracy of a PSA test from 55% to 94%. PSE gives confidence in determining who should proceed to biopsy, and who can be placed on surveillance without additional testing.
1 in 8 men will get prostate cancer in their lifetime. If you are being screened for prostate cancer, talk to your primary care do
11/11/2023
Did you know? 1 in 5 U.S. Veterans will face in their lifetime. 🇺🇸🎗️ This Veterans Day, let's stand with those who've made great sacrifices. Join us in supporting ZERO Prostate Cancer, an organization providing vital support to veterans on their prostate cancer journey. Your contribution can make a real difference. For every dollar you donate, we'll match it up to $5000. Donate here obdx.co/growandgive and share this post with the veterans and active military members in your life.
ZERO Prostate Cancer Veterans | ZERO Prostate Cancer Veterans are a high-risk group for prostate cancer. Learn more about ZERO supports Veterans with prostate cancer.
10/11/2023
Did you know that prostate cancer is the second leading cause of male cancer-related deaths? If caught early, many lives can be extended or even saved. This , we sat down with our CSO, Dr. Alexandre Akoulitchev, to discuss how we aim to transform testing with our 94% accurate prostate screening test. Read more in our new blog post: obdx.co/ProstateQA.
This November, we proudly support ZERO Prostate Cancer’s campaign to raise awareness about for the millions of people impacted by this disease.
Join us by growing facial hair or rocking a boldly blue style, and consider donating at obdx.co/GrowAndGive. For every dollar you contribute, we’ll match up to $5,000. Together, let’s work to .
03/11/2023
This , we’re all in for a cause close to our hearts: raising awareness about the importance of early prostate cancer detection. Join us in spreading the word!
Prostate cancer affects countless men and their families. By prioritizing , we can empower men to take control of their health and provide the best chance of successful treatment. Find out how you can detect prostate cancer with 94% accuracy at 94percent.com.
Stay tuned for exciting awareness and fundraising activities throughout the month!
03/10/2023
We are pleased to announce that OBD has been issued a unique US reimbursement code for our EpiSwitch PSE test for insurance reimbursement under Medicare, Medicaid, and private payors. Read the full announcement here: https://obdx.co/cls.
The PSE test, which launched just last week, boosts the predictive accuracy of the current standard PSA test from 55% to 94% for determining the presence or absence of . The speed of issuance of the reimbursement code demonstrates that the payor groups recognize how important PSE is for screening, not only for the patients but also for the savings to the medical industry.
26/09/2023
Introducing the EpiSwitch® Prostate Screening (PSE) test! EpiSwitch PSE is a simple blood test administered alongside or following a standard PSA test, boosting detection to 94% accuracy. Visit www.94percent.com to find out more.
EpiSwitch® Prostate Screening (PSE) Test | 94% Accurate Detection The EpiSwitch PSE is a simple blood test that detects prostate cancer with 94% accuracy and helps avoid unnecessary biopsies and treatments.
26/09/2023
We’re thrilled to announce during the launch of the highly anticipated EpiSwitch PSE, our 94% accurate prostate cancer detection test, in the US and UK. Read the full announcement here: https://mypse.co/LaunchRNS.
Videos (show all)
